Melanotan II

Overview

Melanotan II is a synthetic cyclic heptapeptide that does something no topical tanning product can: it tells your body to produce more melanin from the inside out. It also triggers erections and suppresses appetite — not as side effects, exactly, but as direct consequences of hitting melanocortin receptors that govern all three of those systems. That broad receptor activity is exactly what makes it interesting, and exactly what makes it dangerous.

The compound was developed at the University of Arizona in the 1980s and 1990s as an analog of alpha-melanocyte stimulating hormone (α-MSH), the body's natural pigmentation signal. The research team's original goal was a tanning agent that could reduce UV exposure and skin cancer risk. What they found instead was a peptide with effects far beyond the skin — one that entered human trials briefly, generated serious safety signals, and never made it to approval.[1]

Today, Melanotan II sits in a legally murky gray zone. It has no FDA approval, no approved compounding pathway in the US, and a documented history of serious adverse events. It's also widely available through research chemical vendors and used by a large number of people who buy it online. If you're reading this page, you probably already know that. What you need is an honest account of what the evidence actually shows.

Mechanism of Action

Your skin's pigmentation system runs on a hormonal signal called α-MSH (alpha-melanocyte stimulating hormone). When UV light hits your skin, keratinocytes release signals that prompt the pituitary to release α-MSH, which then binds to MC1R on melanocytes — the cells that produce melanin. More α-MSH binding means more melanin production, which means darker skin.

Melanotan II is a superpotent synthetic analog of α-MSH.[1] Its cyclic lactam structure — Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10-NH2 — gives it higher receptor binding affinity and greater metabolic stability than the native α-MSH sequence.[1] In plain terms: it delivers a stronger, longer-lasting pigmentation signal than your body's own hormone, without requiring UV exposure to trigger it.

But α-MSH doesn't only act on skin. The same receptor family (MC1R through MC4R) is distributed across the brain, adrenal glands, and peripheral tissues. MC4R in the hypothalamus is particularly relevant — it's a major regulator of energy intake and sexual function. When Melanotan II activates MC4R, it suppresses appetite through hypothalamic pathways and triggers the pro-erectile signaling cascade that researchers later isolated and refined into bremelanotide.

The non-selectivity is the core pharmacological issue. You can't get the tanning effect from MC1R activation without also activating MC3R (which affects energy balance and inflammation) and MC4R (sexual function, autonomic tone). That's not how targeted drugs are designed to work, and it's why the research community moved toward more selective analogs.

What the Evidence Shows

Be clear about what exists here: the human evidence base for Melanotan II is thin. One published pilot Phase 1 trial. A handful of case reports. Animal studies and in-vitro chemistry work. That's it.

The only published human clinical study enrolled 3 normal male volunteers and administered subcutaneous Melanotan II at 0.01 mg/kg on alternating days (saline or MT-II) in a single-blind design over two consecutive weeks.[1] That's an extremely small sample — too small to draw conclusions about efficacy or safety in any population.

What the researchers observed: increased skin pigmentation in the treated subjects, and spontaneous penile erections in 2 of the 3 participants within hours of injection.[1] Nausea was the most frequently reported side effect.[1] The erection finding was striking enough that it redirected a significant portion of subsequent melanocortin research toward sexual dysfunction applications.

This trial established proof-of-concept that Melanotan II does what it's supposed to do in humans. It established nothing about long-term safety, optimal dosing, or what happens in women, older adults, or people with underlying health conditions.

Zebrafish studies have shown that Melanotan II can reverse short-term high-fat diet-induced memory impairment, suggesting MC receptor involvement in metabolic-cognitive interactions.[2] This is interesting biology. It's also zebrafish data, which means it's a long way from clinical relevance.

Side Effects
The side effect picture for Melanotan II comes from a mix of the 1996 pilot trial, case reports, and a large body of user-reported experience. Treat these accordingly: the trial data is from 3 people; the case reports reflect serious outlier events; the user reports are uncontrolled and self-selected.

If you develop sudden flank pain, blood in the urine, severe muscle pain, or an erection lasting more than 4 hours after using Melanotan II, go to an emergency room. Don't wait.